Speakers - 2026

Title: Helicobacter pylori: From nobel discovery to gastric cancer prevention

Abstract

Helicobacter pylori represents one of the most consequential infectious disease discoveries of the twentieth century, fundamentally transforming our understanding of gastric pathology and establishing an unprecedented paradigm linking chronic bacterial infection to human malignancy. This presentation traces the remarkable 40-year scientific journey from Barry Marshall and Robin Warren's revolutionary 1982 discovery—validated through Marshall's legendary self-experimentation—to contemporary population-based screen-and-treat strategies now being implemented for gastric cancer prevention worldwide.

H. pylori infects approximately half of the global population, with prevalence exceeding 70% in developing regions including Southeast Europe. The bacterium's sophisticated virulence mechanisms—including CagA pathogenicity island, VacA cytotoxin, and urease-mediated acid neutralization—enable lifelong colonization and drive a well-characterized pathogenic cascade from chronic active gastritis through atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately gastric adenocarcinoma. This infection-to-cancer sequence, spanning decades, provides a unique window for secondary prevention through timely detection and eradication.

Recent evidence has substantially strengthened the gastric cancer prevention rationale. Meta-analyses demonstrate 45-50% reduction in gastric cancer incidence following successful eradication, with landmark trials from high-incidence regions—including GISTAR-China and Taiwan's population-based programs—providing compelling real-world effectiveness data. Concurrently, escalating antimicrobial resistance, particularly to clarithromycin and levofloxacin, threatens eradication success rates and necessitates susceptibility-guided therapeutic approaches and novel treatment combinations incorporating potassium-competitive acid blockers and bismuth quadruple regimens.

This presentation synthesizes current evidence across three interconnected dimensions: the microbiological and pathogenic mechanisms underlying H. pylori carcinogenesis; the evolving diagnostic landscape from invasive histopathology to noninvasive stool antigen and urea breath testing; and the therapeutic and preventive strategies spanning individual patient management to population-level screen-and-treat implementation. Special consideration is given to implications for Albania and the broader Balkan region, where H. pylori prevalence remains high yet organized screening programs are absent.

The presentation concludes by examining emerging frontiers, including therapeutic vaccine development, microbiome-based interventions, and precision medicine approaches targeting high-risk populations for intensified surveillance and prevention.